One week triple therapy for <i>Helicobacter pylori</i>: a multicentre comparative study

Misiewicz, J. J.; Harris, Adam; Bardhan, Karna Dev; Levi, S; O’Moráin, Colm; Cooper, Barrett R.; Kerr, G. D.; Dixon, M. F.; Langworthy, H; Piper, D. W.

doi:10.1136/gut.41.6.735

Cited by 167 publications

(149 citation statements)

References 7 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…In our study, the eradication rate (87.5%), was similar to the ones reported by other authors (1,2,4,13,15,16,22) and the metronidazole resistance influenced the therapy outcome in 14.3% of the patients. The higher rates of metronidazole resistance in Brazil can be due its widespread use in gynecological infections and parasitic diseases like giardiasis and amebiasis (27) .…”

Section: Discussionsupporting

confidence: 78%

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Eisig¹,

André²,

Silva³

et al. 2003

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. Aim -We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. Methods -Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. Results -One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/ 15 (67%)]. There were six (15%) mild adverse events reports. Conclusions -A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.

show abstract

Section: Discussionsupporting

confidence: 78%

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Eisig¹,

André²,

Silva³

et al. 2003

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Our eradication rate of about 86% with 1-week treatment using a combination of two antibiotics and a proton pump inhibitor compares favourably with results from other studies which used similar 1-week regimens from Europe [12,13], China [14], Turkey [15] and USA [16]. In these studies too, the rates of H. pylori eradication were not significantly higher with prolonged treatment compared to treatment for 1 week.…”

Section: Discussionsupporting

confidence: 76%

Comparison of one week and two weeks of triple therapy for the eradication of <i>Helicobacter pylori</i> in a Sri Lankan population: a randomised, controlled study

Silva¹,

Hewavisenthi

Pathmeswaran³

et al. 2010

Ceylon Med. J.

View full text Add to dashboard Cite

show abstract

“…Studies by Lind and colleagues, published in 1996, 57 and Misiewicz and colleagues, published in 1997, 66 provided the best evidence for parameter estimates on efficacy as they were recent RCTs including UK centres and patients.…”

Section: New Arrivalsmentioning

confidence: 99%

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

Roderick

Davies

Raftery

et al. 2003

Health Technol Assess

113

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model P Roderick NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to prom...

show abstract

One week triple therapy for Helicobacter pylori: a multicentre comparative study

Cited by 167 publications

References 7 publications

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Comparison of one week and two weeks of triple therapy for the eradication of <i>Helicobacter pylori</i> in a Sri Lankan population: a randomised, controlled study

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

Contact Info

Product

Resources

About